Beam Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 436
- Market Cap
- $2.1B
- Introduction
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
Sickle Cell Disease Treatment Market Worth $4.69 Billion
The global sickle cell disease (SCD) treatment market is projected to grow at a CAGR of 19.1% from 2022 to 2030, reaching $4.69 billion. SCD, a common inherited blood disorder, can be detected pre-birth and treated via bone marrow transplants, though donor compatibility is a challenge. Key players like Novartis AG and Pfizer Inc. are expanding their market presence, with recent FDA approvals and acquisitions enhancing treatment options. North America leads the market, with significant growth also expected in Asia Pacific. The development of new drugs and vaccines, alongside public-private partnerships, is driving market expansion.
© Copyright 2025. All Rights Reserved by MedPath